BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9708411)

  • 1. Analysis of life-long strategies to prevent Pneumocystis carinii pneumonia in patients with variable HIV progression rates.
    Wynia MK; Ioannidis JP; Lau J
    AIDS; 1998 Jul; 12(11):1317-25. PubMed ID: 9708411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients.
    Freedberg KA; Hardy WD; Holzman RS; Tosteson AN; Craven DE
    Med Decis Making; 1996; 16(1):29-35. PubMed ID: 8717596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of preventing AIDS-related opportunistic infections.
    Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
    JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.
    Prosty C; Katergi K; Sorin M; Rjeily MB; Butler-Laporte G; McDonald EG; Lee TC
    Clin Microbiol Infect; 2024 Jul; 30(7):866-876. PubMed ID: 38583518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.
    Goldie SJ; Kaplan JE; Losina E; Weinstein MC; Paltiel AD; Seage GR; Craven DE; Kimmel AD; Zhang H; Cohen CJ; Freedberg KA
    Arch Intern Med; 2002 Apr; 162(8):921-8. PubMed ID: 11966344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine.
    Mallolas J; Zamora L; Gatell JM; Miró JM; Vernet E; Valls ME; Soriano E; SanMiguel JG
    AIDS; 1993 Jan; 7(1):59-64. PubMed ID: 8442918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical trial. LFPMI Study Group. Ligue Française de Prévention des Maladies Infectieuses.
    May T; Beuscart C; Reynes J; Marchou B; Leclercq P; Borsa Lebas F; Saba J; Micoud M; Mouton Y; Canton P
    J Acquir Immune Defic Syndr (1988); 1994 May; 7(5):457-62. PubMed ID: 8158539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia.
    Castellano AR; Nettleman MD
    JAMA; 1991 Aug; 266(6):820-4. PubMed ID: 1907671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized study of sulfamethoxazole-trimethoprim versus aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS.
    Nielsen TL; Jensen BN; Nelsing S; Mathiesen LR; Skinhøj P; Nielsen JO
    Scand J Infect Dis; 1995; 27(3):217-20. PubMed ID: 8539544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens.
    Ioannidis JP; Cappelleri JC; Skolnik PR; Lau J; Sacks HS
    Arch Intern Med; 1996 Jan; 156(2):177-88. PubMed ID: 8546551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
    Antinori A; Murri R; Ammassari A; De Luca A; Linzalone A; Cingolani A; Damiano F; Maiuro G; Vecchiet J; Scoppettuolo G
    AIDS; 1995 Dec; 9(12):1343-50. PubMed ID: 8605054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.
    Saah AJ; Hoover DR; Peng Y; Phair JP; Visscher B; Kingsley LA; Schrager LK
    JAMA; 1995 Apr; 273(15):1197-202. PubMed ID: 7707627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study.
    Helweg-Larsen J; Benfield T; Atzori C; Miller RF
    J Antimicrob Chemother; 2009 Dec; 64(6):1282-90. PubMed ID: 19858161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
    Chaisson RE; Keruly J; Richman DD; Moore RD
    Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group.
    Schneider MM; Hoepelman AI; Eeftinck Schattenkerk JK; Nielsen TL; van der Graaf Y; Frissen JP; van der Ende IM; Kolsters AF; Borleffs JC
    N Engl J Med; 1992 Dec; 327(26):1836-41. PubMed ID: 1360145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
    Torres RA; Barr M; Thorn M; Gregory G; Kiely S; Chanin E; Carlo C; Martin M; Thornton J
    Am J Med; 1993 Dec; 95(6):573-83. PubMed ID: 8018144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus.
    Simonds RJ; Hughes WT; Feinberg J; Navin TR
    Clin Infect Dis; 1995 Aug; 21 Suppl 1():S44-8. PubMed ID: 8547511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia.
    Warnock AC; Rimland D
    Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers?
    Bennett CL; Oddone E; Matchar D
    Clin Perform Qual Health Care; 1995; 3(3):156-64. PubMed ID: 10151167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: a two-year Italian multicentric randomized controlled trial. The Italian PCP Study Group.
    Rizzardi GP; Lazzarin A; Musicco M; Frigerio D; Maillard M; Lucchini M; Moroni M
    J Infect; 1996 Mar; 32(2):123-31. PubMed ID: 8708369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.